Open AccessEfficacy and safety of Lactobacillus paracasei CNCM I-1572 and fructo- oligosaccharides in the treatment of patients with irritable bowel syndrome with constipation
Author(s) -
И. Б. Хлынов,
Р. И. Хлынова,
Е. И. Воронова,
Е. В. Гаранина,
И. А. Гурикова,
Т. И. Кобзарь,
М. Э. Лосева,
С. В. Одинец,
О. А. Рябинина,
Л. Т. Сагутдинова,
Е. Б. Фрезе
Publication year - 2021
Publication title -
èksperimentalʹnaâ i kliničeskaâ gastroènterologiâ
Language(s) - English
Resource type - Journals
ISSN - 1682-8658
DOI - 10.31146/1682-8658-ecg-190-6-57-62
Subject(s) - medicine , irritable bowel syndrome , lactobacillus paracasei , constipation , antispasmodic , gastroenterology , adverse effect , defecation , randomized controlled trial , clinical trial , lactobacillus , traditional medicine , food science , chemistry , fermentation
The aim is to study the effect and safety of using the antispasmodic and synbiotic (Lactobacillus paracasei CNCM I-1572 in combination with fructooligosaccharides) in patients with irritable bowel syndrome with constipation. Materials and methods — prospective randomized controlled trial of 80 patients with irritable bowel syndrome with constipation. Patients in the main group (40 people) took mebeverine hydrochloride 200 mg 2 times a day and synbiotic (5x109 CFU Lactobacillus paracasei CNCM I-1572 and 5.2 g fructooligosaccharides) during 28 days. Patients in the control group (40 people) received mebeverine hydrochloride 200 mg 2 times a day during 28 days. Before and after treatment, patients underwent the GSPS questionnaire. Results — in control group clinical remission was achieved in 52.6% of patients. In the main group clinical remission was established in 92.3%, the increase was 39.7% (p <0.01). The relative risk of clinical remission when synbiotic included in the treatment for patients with irritable bowel syndrome with constipation is 1.75 (95% CI 1.28–2.4; p <0.01). When analyzing adverse events of the compared treatment regimens, no statistically significant differences were found (p = 0.75). Conclusion — the results of study demonstrate a significant increase in the effectiveness of therapy in patients with irritable bowel syndrome with constipation with the combined use of antispasmodic and synbiotic.